NeurAxis, Inc. (NRXS) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 71.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.06
• Revenue Growth: 27.52%
• EPS Growth: 62.82%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 8,754,325
• 10 Day Avg. Volume: 47,206
• 30 Day Avg. Volume: 71,918
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: 4.92
• Enterprise Value/Gross Profit: 5.73
• Enterprise Value/Ebitda: -1.90
• 1Y Price Target: $2.50
• Price Target Upside: 1.63% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 48 Neutral
• Price Target: $2.50 ▲(1.63% Upside)

NeurAxis' stock score is primarily influenced by financial instability and valuation concerns, despite positive earnings call guidance and technical indicators suggesting potential stabilization. Strategic milestones offer optimism, but financial restructuring is critical for long-term sustainability.

NeurAxis, Inc. Business Overview & Revenue Model

Company Description

NeurAxis, Inc. (NRXS) is a medical technology company specializing in the development and commercialization of innovative neuromodulation therapies. The company focuses on addressing unmet medical needs in the field of chronic and debilitating neurological conditions. With a commitment to improving patient outcomes, NeurAxis leverages cutting-edge technologies to offer therapeutic solutions that enhance the quality of life for patients suffering from conditions such as chronic pain and other neurological disorders.

How the Company Makes Money

NeurAxis, Inc. generates revenue through the sale of its neuromodulation devices and related therapies. The company's primary revenue stream is derived from the commercialization of its products, which are sold to healthcare providers, hospitals, and clinics. NeurAxis may also receive income from licensing agreements, where it partners with other medical technology companies to expand the reach and adoption of its solutions. Additionally, the company might engage in research and development collaborations, which could provide funding and royalties. Strategic partnerships and collaborations with key industry stakeholders are significant factors that contribute to the company's earnings, enabling it to expand its market presence and enhance its product offerings.

NeurAxis, Inc. Financial Statement Overview

Summary

NeurAxis shows revenue growth, a positive for a biotech firm, but severe financial risks remain due to significant losses, high leverage, and negative equity. Cash flow management is under pressure with negative free cash flows, necessitating strategic adjustments.

Income Statement

NeurAxis has experienced revenue growth from 2023 to 2024, but its profitability remains a concern. The gross profit margin has stayed relatively stable, but net income is deeply negative, indicating significant losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. While the revenue growth is a positive sign, the company struggles with high operating losses.

Balance Sheet

The balance sheet shows critical weaknesses, with negative stockholders' equity indicating more liabilities than assets. The debt-to-equity ratio is not applicable due to negative equity, and the company is highly leveraged. The equity ratio is also concerning, suggesting financial instability. Overall, the balance sheet reflects significant financial risk.

Cash Flow

Cash flow analysis reveals that NeurAxis is burning cash, with negative operating and free cash flows. The company has improved its financing cash flow, which may help sustain operations temporarily. However, the free cash flow to net income ratio is unfavorable, indicating poor cash management relative to earnings. While there's some improvement in cash inflows, the cash flow situation remains a challenge.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.69M	2.46M	2.68M	2.72M	1.93M
Gross Profit	2.32M	2.16M	2.39M	2.25M	1.45M
EBITDA	-7.16M	-9.23M	-4.33M	-2.95M	-3.61M
Net Income	-8.24M	-14.63M	-4.78M	-3.07M	-4.05M
Balance Sheet
Total Assets	4.76M	509.50K	1.48M	760.48K	2.79M
Cash, Cash Equivalents and Short-Term Investments	3.70M	78.56K	253.70K	320.86K	1.90M
Total Debt	473.40K	224.26K	598.82K	439.27K	311.49K
Total Liabilities	2.69M	1.91M	7.05M	1.59M	1.15M
Stockholders Equity	2.07M	-1.40M	-5.57M	-825.66K	1.64M
Cash Flow
Free Cash Flow	-6.13M	-6.77M	-2.36M	-2.24M	-4.17M
Operating Cash Flow	-6.10M	-6.69M	-2.30M	-2.23M	-4.14M
Investing Cash Flow	-27.78K	-71.78K	-61.20K	-1.39K	-27.72K
Financing Cash Flow	9.74M	6.59M	2.29M	661.10K	6.05M

NeurAxis, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.46
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRXS, the sentiment is Negative. The current price of 2.46 is below the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.56, and below the 200-day MA of 2.50, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.61 is Neutral, neither overbought nor oversold. The STOCH value of 17.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRXS.

NeurAxis, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%
NRXS	48 Neutral		―	-2480.49%	―	27.52%	62.82%
GRI	45 Neutral	$3.15M	―	-468.00%	―	―	98.17%
SLRX	30 Underperform	$3.82M	―	-300.16%	―	―	76.18%
PCSA	29 Underperform	$11.68M	―	-212.38%	―	―	57.99%
PTIX	27 Underperform	$2.46M	―	-512.79%	―	―	31.66%
QNRX	25 Underperform	$4.21M	―	-244.31%	―	―	-146.64%

NeurAxis, Inc. Corporate Events

NeurAxis, Inc. Ends Agreement with Masimo Corporation

On July 1, 2025, NeurAxis, Inc. terminated its License and Collaboration Agreement with Masimo Corporation, which had been in place since April 9, 2020, for the NSS-2 Bridge device. As part of the termination, NeurAxis agreed to pay Masimo $200,000, resulting in the cessation of licensing payments and revenue from the device. Additionally, NeurAxis adopted a new Employee Stock Purchase Plan on the same date, allowing employees to purchase company stock at a discount, with stockholder approval required within 12 months.

The most recent analyst rating on (NRXS) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on NeurAxis, Inc. stock, see the NRXS Stock Forecast page.

NeurAxis, Inc. Approves Key Proposals at Annual Meeting

On May 29, 2025, Neuraxis, Inc. held its annual meeting of stockholders in Carmel, Indiana, where a quorum was achieved with 59.22% of votes represented. During the meeting, six directors were elected for a one-year term, and the appointment of Rosenberg Rich Baker Berman, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Additionally, the issuance of 20% or more of the company’s outstanding common stock upon conversion of Series B Convertible Preferred Stock was approved.

NeurAxis, Inc. Releases Investor Presentation

On May 23, 2025, Neuraxis, Inc. released an investor presentation on its website, outlining the company’s strategy, performance, and future objectives. This presentation, which includes forward-looking statements, is not considered filed under the Securities Exchange Act of 1934 and is not subject to its liabilities.

NeurAxis, Inc. Announces $5 Million Stock Offering

On May 20, 2025, NeurAxis, Inc. entered into a securities purchase agreement with institutional investors to sell 1,538,461 shares of its common stock at $3.25 per share, aiming to raise approximately $5.0 million. The offering, expected to close on May 22, 2025, is intended to provide funds for working capital and general corporate purposes. Craig-Hallum Capital Group LLC is acting as the exclusive placement agent for this transaction. This move is part of NeurAxis’s strategy to strengthen its financial position and support its ongoing clinical trials and operations in the neuromodulation therapy market.

NeurAxis, Inc. Receives $1 Million from Warrant Exercises

NeurAxis, Inc. has reached a settlement agreement regarding lawsuits initiated by various parties between February 2019 and July 2022. On May 15, 2025, the company agreed to pay $750,000 in 12 monthly installments starting January 2026, in exchange for the waiver of all claims by the Releasing Parties. Additionally, between May 20 and May 21, 2025, NeurAxis received $1 million from warrant exercises and issued 430,580 shares of Common Stock, while three holders of Series B Preferred Stock converted their shares into 342,016 shares of Common Stock.